Forest Laboratories, Inc.
http://www.frx.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Forest Laboratories, Inc.
Vaccinex Sees Mixed Signals In Huntington’s Study
However, Vaccinex sees possible efficacy for SEMA4D inhibition in later-stage Huntington’s as well as Alzheimer’s disease. Pepinemab is also being studied with Keytruda in head-and-neck cancer.
Finance Watch: Brent Saunders Plots Return To Deal-Making With A SPAC IPO
Public Company Edition: The former Allergan CEO is taking a special purpose acquisition corporation public to generate $460m for deals in familiar biopharma niches. Also, IPOs are expected to keep up a robust pace in the fall and Albireo raises $160m on the success of its drug for pediatric liver diseases.
Finance Watch: One Small Pain Drug Maker And Three Biotech SPACs Launch IPOs
After a brief lull in US initial public offerings, PainReform and three special purpose acquisition companies kicked off September’s IPOs. Also, Immunovant offering grossed $173.9m, Carlyle Group bought 5% stake in China’s Salubris and Erasca increased its series B to $236m.
The Factory Floor: Carbogen Amcis, PCI Pharma And Vetter Expand In Europe
Carbogen Amcis, LGM Pharma, Vetter and PCI Pharma are focusing on expanding their businesses, while ChemWerth has filed its 500th drug master file for clevidipine with the FDA.
Company Information
- Other Names / Subsidiaries
-
- Aptalis Pharma Inc. (Axcan Pharma, Inc.
- Eurand N.V.
- Mpex Pharmaceuticals, Inc.)
- Cerexa, Inc.
- Clinical Data, Inc.